Scientific Leader Area 3
Area 3 combines the research efforts in the tightly linked fields of metabolic, hormonal, inflammatory and infectious disease. Projects in Area 3 deal with the lack of reliable, easy assessable and cheap biomarker for either diagnostic and risk assessment purposes or prediction of treatment response and hence treatment choice.
CBmed Projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.MORE ABOUT ALL PROJECTS AND PARTNERS
Metabolomic, immunological and genomic analyses as well as innovative molecular and cellular techniques will be used to identify novel biomarkers that can be used in early diagnosis of abnormal metabolic processes including autoimmune, endocrine, cardiovascular, inflammatory and infectious diseases.
Area 3 is closely linked to Area 2 through a focus on obesity, type 2 diabetes, non-alcoholic fatty liver disease, and liver cirrhosis, which are all conditions that put subjects at an increased the risk of cancer. In turn, cancer and chemotherapeutic regimens increase the risk for infectious diseases and disturbed glucose metabolism. Therefore, there is a clear and tight interaction between Area 3 and Area 2 with regard to the content and potential biomarkers identified in Area 3.
As the methods used in Area 3, in particular microbiome analyses and metabolomics will gather large amounts of data, a close collaboration with Area 1 is vital for the identification of patterns and finally biomarkers in the datasets. Moreover, the use of Biobank Graz will be essential for validation of potential biomarkers identified in projects of Area 3.